{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:30:02Z","timestamp":1786120202443,"version":"build-2736575974"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1097\/rhu.0b013e31823a46ed","type":"journal-article","created":{"date-parts":[[2011,11,30]],"date-time":"2011-11-30T07:21:59Z","timestamp":1322637719000},"page":"416-420","source":"Crossref","is-referenced-by-count":18,"title":["Beh\u00e7et Disease"],"prefix":"10.1097","volume":"17","author":[{"given":"Ana Cec\u00edlia Diniz","family":"Oliveira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Let\u00edcia Pirozzi","family":"Buosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00edvia Almeida","family":"Dutra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre Wagner Silva","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210207","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJM199910213411707","article-title":". Behcets disease.","volume":"341","author":"Sakane","year":"1999","journal-title":"N Engl J Med"},{"key":"R2-2-20210207","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.berh.2004.02.008","article-title":"Behcets disease.","volume":"18","author":"Marshall","year":"2004","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R3-2-20210207","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1034\/j.1399-0039.1999.540301.x","article-title":". Behcets disease, the Silk Road and HLA-B51: historical and geographical perspectives.","volume":"54","author":"Verity","year":"1999","journal-title":"Tissue Antigens"},{"key":"R4-2-20210207","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.autrev.2009.10.005","article-title":". Etiopathogenesis of Behcets disease.","volume":"9","author":"Mendonza-Pinto","year":"2010","journal-title":"Autoimmun Rev"},{"key":"R5-2-20210207","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jaut.2009.02.011","article-title":". Behcets diseasea contemporary review.","volume":"32","author":"Mendes","year":"2009","journal-title":"Autoimmun Rev"},{"key":"R6-2-20210207","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1136\/ard.2008.087957","article-title":". Management of Behcet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behcet disease.","volume":"68","author":"Hatemi","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R7-2-20210207","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1136\/ard.2007.080432","article-title":". EULAR Recommendations for the management of Behcet disease.","volume":"67","author":"Hatemi","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R8-2-20210207","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s10067-008-1081-z","article-title":". Faraway from the Silk Route: demographic and clinical features of Behcets disease in 106 Brazilian patients.","volume":"28","author":"Neves","year":"2009","journal-title":"Clin Rheumatol"},{"key":"R9-2-20210207","first-page":"235","article-title":"Clinical aspects of Behcets syndrome in Brazil: a review of 16 cases.","volume":"34","author":"Tunes","year":"2009","journal-title":"Acta Rheumatol Port"},{"key":"R10-2-20210207","first-page":"339","article-title":". Behcets disease in Brazila review of 49 cases with emphasis on ophthalmologic complications.","volume":"35","author":"Barra","year":"1991","journal-title":"Jpn J Ophthalmol"},{"key":"R11-2-20210207","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1136\/bjo.78.12.927","article-title":". S-antigen specific T cell clones from a patient with Behcets disease.","volume":"78","author":"Yamamoto","year":"1994","journal-title":"Br J Ophthalmol"},{"key":"R12-2-20210207","first-page":"343","article-title":". The role of ambiental agents in Behcets disease.","volume":"62","author":"Heymann","year":"1995","journal-title":"Rev Rheum Engl Ed"},{"key":"R13-2-20210207","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/rheumatology\/34.10.932","article-title":". Sensitivity and specificity of different diagnostic criteria for Behcets disease according to the latent class approach.","volume":"34","author":"Ferraz","year":"1995","journal-title":"Br J Rheumatol"},{"key":"R14-2-20210207","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1590\/S1807-59322007000600005","article-title":". Anti-endothelial cell antibodies and central nervous system involvement in Behcets disease.","volume":"62","author":"Souza","year":"2007","journal-title":"Clinics (Sao Paulo)"},{"key":"R15-2-20210207","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s10067-009-1261-5","article-title":". Neutrophil hyperchemotaxis in Behcets disease: a possible role for monocytes orchestrating bacterial-induced innate immune responses.","volume":"28","author":"Neves","year":"2009","journal-title":"Clin Rheumatol"},{"key":"R16-2-20210207","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1590\/S0004-27492010000100007","article-title":". Chlorambucil and cyclosporine A in Brazilian patients with Behcets disease uveitis: a retrospective study.","volume":"73","author":"Zaghetto","year":"2010","journal-title":"Arq Bras Oftalmol"},{"key":"R17-2-20210207","first-page":"66","article-title":". Doenca de Behcet: estudo de 22 casos.","volume":"37","author":"Aguiar","year":"1997","journal-title":"Rev Bras Reumatol"},{"key":"R18-2-20210207","first-page":"1078","article-title":"Criteria for diagnosis of Behcets disease.","volume":"335","year":"1990","journal-title":"Lancet"},{"key":"R19-2-20210207","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/ard.43.1.70","article-title":". The pathergy test and Behcets syndrome in Britain.","volume":"43","author":"Davies","year":"1984","journal-title":"Ann Rheum Dis"},{"key":"R20-2-20210207","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/art.22500","article-title":". Epidemiology and clinical course of Behcets disease in the Reggio Emilia Area of Northern Italy: a seventeen-year population-based study.","volume":"57","author":"Salvarani","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R21-2-20210207","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3346\/jkms.2001.16.5.615","article-title":". Epidemiologic and clinical survey of Behcets disease in Korea: the first multicenter study.","volume":"16","author":"Bang","year":"2001","journal-title":"J Korean Med Sci"},{"key":"R22-2-20210207","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1136\/ard.43.6.783","article-title":". Influence of age of onset and patients sex on the prevalence and severity of manifestations of Behcets syndrome.","volume":"43","author":"Yazici","year":"1984","journal-title":"Ann Rheum Dis"},{"key":"R23-2-20210207","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1046\/j.1365-4362.2003.01741.x","article-title":"Evaluation of clinical findings according to sex in 2313 Turkish patients with Behcets disease.","volume":"42","author":"Tursen","year":"2003","journal-title":"Int J Dermatol"},{"key":"R26-2-20210207","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1002\/1529-0131(200111)44:11<2686::AID-ART448>3.0.CO;2-H","article-title":". A double-blind trial of colchicine in Behcets syndrome.","volume":"44","author":"Yurdakul","year":"2001","journal-title":"Arthritis Rheum"},{"key":"R27-2-20210207","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000246336","article-title":". Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behcets disease.","volume":"192","author":"Calguneri","year":"1996","journal-title":"Dermatology"},{"key":"R28-2-20210207","doi-asserted-by":"crossref","first-page":"443","DOI":"10.7326\/0003-4819-128-6-199803150-00004","article-title":". Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial.","volume":"128","author":"Hamuryudan","year":"1998","journal-title":"Ann Intern Med"},{"key":"R29-2-20210207","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1346-8138.2002.tb00263.x","article-title":"Dapsone in Behcets disease: a double-blind, placebo-controlled, cross-over study.","volume":"29","author":"Sharquie","year":"2002","journal-title":"J Dermatol"},{"key":"R30-2-20210207","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1002\/art.1780391216","article-title":". The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behcets. A randomized clinical trial.","volume":"39","author":"Calguneri","year":"1996","journal-title":"Arthritis Rheum"},{"key":"R31-2-20210207","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1056\/NEJM199002013220501","article-title":". A controlled trial of azathioprine in Behcets syndrome.","volume":"322","author":"Yazici","year":"1990","journal-title":"N Engl J Med"},{"key":"R32-2-20210207","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0190-9622(96)90006-7","article-title":"Behcets disease. Report of twenty-five patients from the United States with prominent mucocutaneous involvement.","volume":"34","author":"Mangelsdorf","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"R33-2-20210207","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/0190-9622(91)70156-V","article-title":". Low-dose weekly methotrexate for unusual neutrophilic vascular reactions: cutaneous polyarteritis nodosa and Behcets disease.","volume":"24","author":"Jorizzo","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"R34-2-20210207","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/bjo.76.4.241","article-title":". Low dose cyclosporine A versus pulsed cyclophosphamide in Behcets syndrome: a single masked trial.","volume":"76","author":"Ozazgan","year":"1992","journal-title":"Br J Ophthalmol"},{"key":"R35-2-20210207","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s10067-005-0070-8","article-title":". CNS involvement occurs more frequently in patients with Behcets disease under cyclosporin A (CSA) than under other medicationsresults of a retrospective analysis of 117 cases.","volume":"25","author":"Kotter","year":"2006","journal-title":"Clin Rheumatol"},{"key":"R36-2-20210207","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S0161-6420(99)90120-3","article-title":". Central nervous system symptoms in patients with Behcet disease receiving cyclosporine therapy.","volume":"106","author":"Kotake","year":"1999","journal-title":"Ophthalmology"},{"key":"R37-2-20210207","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1046\/j.1442-9071.2001.00445.x","article-title":". Central nervous system symptoms in a population of Behcets disease patients with refractory uveitis treated with cyclosporine A.","volume":"29","author":"Kato","year":"2001","journal-title":"Clin Exp Ophthalmol"},{"key":"R38-2-20210207","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s00415-010-5885-9","article-title":"Cerebral venous thrombosis in Behcets disease: a systematic review.","volume":"258","author":"Aguiar de Sousa","year":"2011","journal-title":"J Neurol"},{"key":"R39-2-20210207","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0022-510X(98)00165-8","article-title":"Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behcets disease.","volume":"159","author":"Hirohata","year":"1998","journal-title":"J Neurol Sci"},{"key":"R40-2-20210207","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/0-306-48382-3_117","article-title":"Low dose MTX for progressive neuro-Behcets disease. A follow-up study for 4 years.","volume":"528","author":"Kikuchi","year":"2003","journal-title":"Adv Exp Med Biol"},{"key":"R41-2-20210207","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/rheumatology\/kem034","article-title":". Anti-TNF therapy in the management of Behcets diseasereview and basis for recommendations.","volume":"46","author":"Sfikakis","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"R42-2-20210207","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/bjo.2009.158840","article-title":". Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behcet disease.","volume":"94","author":"Yamada","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"R43-2-20210207","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10067-007-0685-z","article-title":". Treatment of venous thrombosis associated with Behcets disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation.","volume":"27","author":"Ahn","year":"2008","journal-title":"Clin Rheumatol"}],"container-title":["JCR: Journal of Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/RHU.0b013e31823a46ed","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:25:29Z","timestamp":1786047929000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00124743-201112000-00002"}},"subtitle":["Clinical Features and Management in a Brazilian Tertiary Hospital"],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/rhu.0b013e31823a46ed","relation":{},"ISSN":["1076-1608"],"issn-type":[{"value":"1076-1608","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}